RDGL
Vivos Inc.0.0691
-0.0026-3.65%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
31.41MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
8-K
Vivos enters India market
Vivos Inc. launched Vivos Scientific India LLP on September 17, 2025, as a wholly owned entity to build a manufacturing center and expand human therapies in India. This move targets commercialization of therapies there while generating more human trial data for FDA support. Strategic expansion bolsters global reach. Yet risks include regulatory hurdles in new markets.
10-Q
Q2 FY2025 results
Vivos Inc. posted Q2 FY2025 revenue of $15,000, up 11.1% y/y from $13,500, yet swung to a gross loss of $34,753 from a $2,720 profit, driven by higher cost of goods sold from inventory buildup for IsoPet therapies. Operating loss widened to $674,772, a 29.2% y/y increase, fueled by elevated professional fees including $494,935 in RSU vesting and ramped research and development at $107,965. Net loss hit $645,513, or $0.00 per diluted share on 453.5M shares, consistent with basic due to anti-dilutive effects. Cash climbed to $2.7M after $1.5M from Regulation A+ stock sales, funding FDA IDE pursuits and India trials. No debt burdens the balance sheet. Regulatory hurdles could delay human therapy rollout.
10-Q
Q1 FY2025 results
Vivos Inc. posted Q1 FY2025 revenue of $26,748, up sharply from $4,500 a year earlier, driven by IsoPet treatments and new clinic certifications, though gross margins stayed negative at a $9,083 loss amid higher costs. Operating expenses climbed 48% y/y to $854,449 (derived), fueled by professional fees and R&D for human trials in India and the US, yielding an operating loss of $863,532 versus $577,129 last year; net loss widened to $834,696, with the gap to operating loss under 5% from minor interest income. Cash swelled to $3.3M after raising $1.5M via stock sales, funding $455K in operating burn—enough runway for now. No debt burdens the balance sheet. Regulatory hurdles in FDA approvals loom large.
10-K
FY2024 results
Vivos Inc. posted FY2024 revenue of $27,995, up 43.6% y/y from $19,500, driven by IsoPet® therapies and a new $4,995 clinic certification fee, though gross loss narrowed to $2,984 from $6,036 amid rising clinic network to 13 sites. Operating expenses dipped 6.7% to $2,601,400, yielding an operating loss of $2,604,384 versus $2,793,146 prior year, with net loss edging to $2,910,448 after $381,000 warrant exchange hit. Q4 momentum shone through expanded certifications and India clinical trial launch, accelerating commercialization while R&D spend halved to $324,629 annually. Cash swelled to $2,212,548, funding $3.5M yearly needs via Reg A raises. No annual guidance disclosed. Yet regulatory delays could stall quarterly progress.
AORT
Artivion, Inc.
45.91+0.54
ARAY
Accuray Incorporated
1.02-0.03
GTHP
Guided Therapeutics, Inc.
0.25-0.02
IRMD
iRadimed Corporation
96.87-0.15
NVCR
NovoCure Limited
12.93-0.04
PETV
PetVivo Holdings Inc.
1.16-0.03
RBOT
Vicarious Surgical Inc.
2.43-0.04
RCEL
Avita Medical, Inc.
3.33-0.07
SNWV
SANUWAVE Health, Inc.
31.46-0.18
VVOS
Vivos Therapeutics, Inc.
2.02+0.00